243 related articles for article (PubMed ID: 17763605)
1. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Scheinfeld N
J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
[TBL] [Abstract][Full Text] [Related]
2. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
3. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
4. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Geskin L; Malone DC
J Dermatolog Treat; 2018 Aug; 29(5):522-530. PubMed ID: 29191068
[TBL] [Abstract][Full Text] [Related]
5. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
6. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
7. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
8. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
9. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
11. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
12. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
15. Optimal combination with PUVA: rationale and clinical trial update.
Stadler R
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
[TBL] [Abstract][Full Text] [Related]
16. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
17. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies for cutaneous T-cell lymphomas.
Horwitz SM
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
[TBL] [Abstract][Full Text] [Related]
19. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
20. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
